Home > Boards > US Listed > Biotechs >

iBio, Inc. (IBIO)

IBIO RSS Feed
Add IBIO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, JPetroInc, [SMART MONEY] , Top Penny, YJ4LIFE
Search This Board: 
Last Post: 9/29/2020 9:13:03 AM - Followers: 500 - Board type: Free - Posts Today: 2


https://www.ibioinc.com/technology/glycan-engineering
 




(NYSE MKT: IBIO)
https://www.ibioinc.com/
 

Company Overview

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.


========================================================================================================================================================================

https://www.otcmarkets.com/stock/IBIO/disclosure

https://www.otcmarkets.com/stock/IBIO/news

https://www.otcmarkets.com/stock/IBIO/security

https://www.otcmarkets.com/stock/IBIO/profile

https://www.otcmarkets.com/stock/IBIO/quote

https://www.otcmarkets.com/stock/IBIO/overview

 

FastPharming™ Advantages



https://www.ibioinc.com/about/what-we-do
Because the cell line development phase is eliminated, FastPharming offers significant time savings compared to traditional expression platforms.
For instance, iBio produces milligram quantities of protein in as little as 6 weeks, gram quantities in 3 months, and greater than 10g of cGMP material in only 8 months.Additionally, 
FastPharming processes are easily scalable, produce high quality product, are cost efficient, deliver improved safety, and facilitate superior glycosylation control.

IBio uses the FastPharming System to quickly produce biotherapeutic and vaccine candidates for unmet medical needs.
In the area of human disease, IBIO-100 targets fibrosis, a leading world-wide cause of organ failure.
IBIO-200 is a virus-like particle (VLP) vaccine designed as a rapid medical countermeasure solution to the COVID-19 outbreak.

Technology Applications


The FastPharming platform produces a variety of recombinant products including:

  • Biobetter and biosimilar antibodies
    Antigens for subunit vaccine design
    Virus-like particles (VLP)
    Lysosomal enzymes
    Blood factors and cytokines
    Scaffolds, maturogens and materials for 3D Bioprinting and biofabrication


     
https://www.ibioinc.com/scientific-publications
 

The COVID-19 pandemic sweeping across the globe is pushing innovation to the cutting edge throughout the biopharma industry.
More rapid development of novel diagnostics, therapeutics,
and vaccines is acutely needed to mitigate further spread of the virus and prevent its reoccurrence in the future.
iBio is offering its FastPharmingTM  Contract Manufacturing Services to vaccine and therapeutic developers to address the need
for speeding time-to-clinic for new antigens, antibodies, and other protein biologics using a plant-based expression system.
In addition, iBio is developing its own proprietary solutions, notably IBIO-200, a virus-like particle (VLP) vaccine candidate for  COVID-19 disease.

Potential Vaccine Platforms

The traditional approach to vaccines is to use live or killed viruses to generate immune responses.
Development, approval, and commercialization of these types of vaccines can take several years, a model that is clearly unfeasible during this pandemic.
New approaches use a reductionist approach by identifying key viral components that can be incorporated into a vaccine that elicits a strong immune response and is also safe and easy to manufacture.1

Such approaches include vaccines that rely on recombinant DNA or messenger RNA (mRNA).
San Diego-based Inovio Pharmaceuticals, the first company to advance a vaccine (INO-4700) against MERS-CoV into human testing,
is developing a DNA-based vaccine against COVID-19, while both Cambridge, Massachusetts-based Moderna and German biotech CureVac are developing mRNA-based vaccines.
There are concerns with many of these approaches, however, particularly DNA and mRNA vaccines.
Questions have been raised about their cold-chain requirements compared with traditional vaccine technology platforms.
These solutions provide great hope but carry significant risk. 

At present, six COVID-19 or SARS-CoV-2 phase I clinical trials are listed in clinicaltrials.gov, although there are likely more in the works, as registration in the database is not mandatory until phase II.

iBio’s VLP Solutions

Virus-like particles (VLPs) represent a promising alternative to soluble antigens, as their shape, size, repetitive antigen structure,
and geometry have been shown to trigger stronger immune response, both humoral and cellular.2 VLPs are artificial
constructs comprising multiple proteins organized to resemble a virus, but without including any viral genetic material, thereby rendering them non-infectious.
Because they have the components and conformation of the native virus, they can engender stronger and broader immune responses than the antigen itself.

In addition, VLPs can be produced as cost-effectively as other novel platform technologies being used for COVID-19 vaccine development
and do not present additional safety concerns compared with those associated with DNA- and mRNA-based solutions.

iBio has extensive capability in this area, having developed plant-based bioprocesses that generate VLPs with the
same structures as more traditional methods but via more efficient manufacturing routes. VLP platforms like iBio’s are advantageous because,
in addition to obtaining high yields of the individual VLP components, the components automatically self-assemble into a spherical VLP,
simplifying both the upstream and downstream purification processes involved in VLP manufacture.

The recent phase III clinical success of a VLP-based influenza vaccine produced in the N. benthamiana system
(NCT03739112, NCT03301051), both in terms of efficacy and safety, demonstrates the potential for plant-based VLP vaccine development.3 

IBio-200: A VLP-Based COVID-19 Vaccine Candidate

IBIO-200 is iBio’s lead COVID-19 vaccine candidate.  iBio uses Woodchuck hepatitis virus and human hepatitis B virus core proteins
fused to COVID-19 receptor-binding motif (RBM), which self-assemble into empty nanoparticles.
The resulting VLPs form 40- to 50-nm diameter nanoparticles. The antigen is displayed in a repetitive structure and geometry,
and the particle is decorated with oligomannose molecules to more closely resemble the structure of naturally occurring viruses.  
Oligomannose glycosylation is thought to lead to better cellular uptake of the VLPs by antigen-presenting cells via the mannose receptor.
As with other VLP-derived vaccines, IBIO-200 is designed to interact with immune cells differently than soluble antigens.

The production of IBIO-200 follows standard and highly optimized protocols. Plants are seeded,
germinated, and grown to 5 weeks of age in environmentally controlled grow rooms.
At 5 weeks, plants are vacuum infiltrated with Agrobacterium containing transient plant-specific expression vectors encoding COVID-19 antigen constructs.
After infiltration, the vector drives vaccine expression for 5–7 days; plant material is shredded, and total soluble protein extracted.
Preliminary scalable downstream processes have been designed, including concentration and buffer exchange of clarified extract capture and polishing chromatography.

For evaluation purposes, the first screenings measured expression and protein stability.
Selected candidates will then be injected into mice for an initial immunization study.
IgG response, cytokine profiling, and results of virus neutralization assays will dictate a second candidate screening.
Subsequently, selected candidates will enter toxicology studies in appropriate animal models to support an IND filling.
A lead candidate and a back-up will then be selected for further in vivo efficacy studies.

In parallel, iBio will develop a process that is scalable to cGMP manufacturing, prepare manufacturing documentation, and develop QC release assays.
The FastPharming manufacturing system delivers a tightly controlled particle size, providing considerable quality and scale-up advantages,
as uniform antigen display enables better dose definition and higher product yields. 

All of this work will be based on technology proven successful for the clinical development of vaccine candidates in iBio’s U.S.-based,
large-scale production facility with all cGMP, QA, QC, scale-up, and regulatory resources;
the facility is self-contained and secure with highly reliable logistics.

Extensive Vaccine Experience at iBio

iBio’s FastPharming facility was originally constructed in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA),
part of the U.S. Department of Defense (DoD), which was exploring a range of technologies that could enable faster responses to outbreaks.
Plant-based expression technology won out, and the facility was one of three commercial sites comprising the “Blue Angel” initiative.

As part of the DARPA Blue Angel H1N1 Program, iBio’s facility was designed and built to manufacture kilogram quantities of
recombinant proteins within months versus the historically longer time frames needed for more traditional systems.
Its rapid launch to production has been designed specifically for medical countermeasure responses.
The iBio facility is among the largest biotherapeutic production facilities in the world for the production of recombinant protein in N. benthamiana,
with a current capacity to produce bulk clinical protein at the scale of approximately 500 million doses per year.

iBio technology has been used to produce a number of prophylactic vaccines, including soluble pathogen antigens formulated with adjuvants against anthrax,
H5N1 influenza, H1N1 influenza and hookworm, and a virus-like particle (VLP) formulated with an adjuvant against malaria.
Phase I clinical studies have been completed for all of these vaccine candidates.

 




 

*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.

 

 




 

 

IBIO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IBIO News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 09/28/2020 06:07:20 AM
IBIO News: iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201 09/09/2020 08:45:10 AM
IBIO News: iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic 08/28/2020 07:15:10 AM
IBIO News: Amended Statement of Beneficial Ownership (sc 13d/a) 08/13/2020 04:55:48 PM
IBIO News: Current Report Filing (8-k) 08/13/2020 04:01:38 PM
PostSubject
#24215  Sticky Note 3 Small-Cap Coronavirus Stocks That Could Skyrocket YJ4LIFE 08/02/20 05:55:04 PM
#25017   IBIO developing 5 acre field in Texas for JPetroInc 09/29/20 09:13:03 AM
#25016   Buying more in a few days. Top Penny 09/29/20 06:09:11 AM
#25015   Good info. These guys have been back and EL-Eighty2020 09/28/20 11:04:20 PM
#25014   when it runs, you won't even see $2.50 JPetroInc 09/28/20 10:14:28 PM
#25013   Article came out today at 3:51pm. https://investorplace-com.cdn.ampproject.org/ Mencia 09/28/20 09:43:21 PM
#25012   Article came out today at 3:51pm. https://investorplace-com.cdn.ampproject.org/ Mencia 09/28/20 09:42:44 PM
#25011   if this starts heading back over $2.50 then Nebuchadnezzar 09/28/20 12:12:55 PM
#25010   No as I don't believe Tom Isett or JPetroInc 09/27/20 06:00:23 PM
#25008   Do you see this affecting SP in the Inspector121 09/27/20 05:15:21 PM
#25007   $ibio $2.09 ^ 0.16 (8.29%) Taurus69 09/27/20 03:04:14 PM
#25006   "consolidation in the CDMO industry" JPetroInc 09/27/20 01:34:39 PM
#25005   the IBIO vs. Fraunhofer patent suit is valued JPetroInc 09/27/20 10:37:05 AM
#25004   From Ask Warren HQ @askwarrenhq This is a parody account! stockmavin 09/27/20 10:17:11 AM
#25003   IBIO's Complaint contains twelve (12) counts: JPetroInc 09/26/20 09:33:29 PM
#25002   www.stockscores.com/chart.asp?TickerSymbol=IBIO&TimeRange=90&Interval=d&V mick 09/26/20 09:18:06 PM
#25001   IBIO, INC., Plaintiff, v. FRAUNHOFER USA, INC., Defendant JPetroInc 09/26/20 08:24:21 PM
#25000   when you see IBIO trading for $25 to JPetroInc 09/26/20 08:14:42 PM
#24999   You think that is for real? Inspector121 09/26/20 04:17:34 PM
#24998   Therapeutic Proteins from Plants JPetroInc 09/26/20 01:04:12 PM
#24996   Check out the institutional investment chart for IBIO, EL-Eighty2020 09/26/20 12:13:01 PM
#24995   Don’t be playing with us like that!!! EL-Eighty2020 09/26/20 12:12:22 PM
#24994   IBIO to be Scooped Up in All Cash Transaction JPetroInc 09/25/20 10:41:38 PM
#24993   nice little move today JPetroInc 09/25/20 09:29:48 PM
#24992   iBio Inc (IBIO) mick 09/25/20 08:07:39 PM
#24991   $2.50+ close is all that matters now. if Nebuchadnezzar 09/25/20 04:04:32 PM
#24990   IBIO is a development stage company JPetroInc 09/25/20 01:29:42 PM
#24989   Do you think they will show some positive? EL-Eighty2020 09/25/20 01:21:48 PM
#24988   expecting IBIO's ER on Monday, 09/28/20 JPetroInc 09/25/20 01:13:40 PM
#24987   LOL - the worlds gone mad.... JPetroInc 09/25/20 01:09:46 PM
#24986   IBIO really hunkering down around $2.00. kind of Nebuchadnezzar 09/25/20 11:58:30 AM
#24985   Well that's a bit concerning... I posted it doebop 09/25/20 09:32:23 AM
#24984   Waiting on IBIO funding... JPetroInc 09/25/20 09:22:26 AM
#24983   "Human 2.0"? A Wake-Up Call To The World JPetroInc 09/24/20 10:07:12 PM
#24982   I could not help it, bought back in tigertiger88 09/24/20 12:09:26 PM
#24981   From Ibio page alvaroc2 09/23/20 06:44:43 PM
#24980   Thank you, same to you tigertiger88 09/23/20 11:24:55 AM
#24978   good luck tiger JPetroInc 09/23/20 01:35:23 AM
#24977   GLTA, Im out tigertiger88 09/22/20 12:51:22 PM
#24976   what a shame or sham tigertiger88 09/22/20 10:28:47 AM
#24975   Timberrrrrrr tigertiger88 09/22/20 10:00:12 AM
#24974   Holding strong optiontrades 09/21/20 02:57:43 PM
#24972   this site is an outrage and outta control JPetroInc 09/21/20 03:05:57 AM
#24971   Bio-International 2019 w/Tom_Isset & Dr. Sylvain Marcel JPetroInc 09/20/20 07:55:54 PM
#24970   Stemming the Next Pandemic: The Final Customer is JPetroInc 09/20/20 02:18:38 PM
#24969   3 Compelling Biotech Stocks to Consider Buying While JPetroInc 09/20/20 02:16:15 PM
#24968   IBIO is a powder keg JPetroInc 09/20/20 02:03:23 PM
#24967   yip... JPetroInc 09/20/20 02:00:49 PM
#24966   never say never JPetroInc 09/20/20 02:00:10 PM
#24965   IBIO-volume past 30 days is pretty indicative of Nebuchadnezzar 09/20/20 01:40:35 PM
#24964   Simply saying -That will never happen - guay 09/20/20 06:32:23 AM
PostSubject
Consent Preferences